Srinagarind Hospital experience in concurrent chemoradiation for 100 patients with stage IB2 to IVA uterine cervical cancer
- 25 December 2007
- journal article
- Published by Springer Science and Business Media LLC in Radiation Medicine
- Vol. 25 (10), 502-510
- https://doi.org/10.1007/s11604-007-0172-0
Abstract
The aim of this study was to determine responses, acute adverse effects, and survival outcomes of women with stage IB2 to IVA treated with weekly cisplatin concurrent with pelvic irradiation at Srinagarind Hospital. The medical records of 100 women with cervical cancer stage IB2 to IVA who were treated with weekly cisplatin 40 mg/m2 concurrent with pelvic radiotherapy at Srinagarind Hospital between January 2003 and June 2006 were reviewed and analyzed. During the study period, 100 women were eligible for analysis, with a mean age of 46 years (range 24–60 years). Distribution according to International Federation of Gynecology and Obstetrics (FIGO) staging was IB2 1.0%, IIB 47.0%, IIIB 51.0%, and IVA 1.0%, respectively. A total of 86 patients received five or more cycles of weekly cisplatin. Grade 3 and 4 hematologic toxicities were found in 6.0%. The overall response rate was 97.0%. Complete response was achieved in 86 patients (86.0%) and partial response in 11 patients (11.0%). Stable disease was found in 1 patient (1.0%) but no progressive disease was found. Progression-free survival and overall survival rate were 69.6% and 96.1%, respectively. Weekly cisplatin (40 mg/m2) concurrent with pelvic irradiation for locally advanced cervical cancer was effective with acceptable toxicity in Thai women.Keywords
This publication has 40 references indexed in Scilit:
- A randomized phase III trial of concurrent chemoradiotherapy in locally advanced cervical cancer: Preliminary resultsGynecologic Oncology, 2007
- Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: A phase I/II study of the Gynecologic Oncology GroupGynecologic Oncology, 2006
- Impact of hemoglobin on survival of cervical carcinoma patients treated with concurrent chemoradiotherapy is dependent on lymph node metastasis findings by magnetic resonance imagingInternational Journal of Gynecologic Cancer, 2006
- Concurrent cisplatin/gemcitabine chemotherapy along with radiotherapy in locally advanced cervical carcinoma: A phase II trialGynecologic Oncology, 2006
- The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancerCritical Reviews in Oncology/Hematology, 2004
- Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: Effect on progression-free survivalInternational Journal of Gynecologic Cancer, 2003
- Hydroxyurea, 5-Fluorouracil Infusion, and Cisplatin Adjunct to Radiation Therapy in Cervical Carcinoma: A Phase I–II Trial of the Gynecologic Oncology GroupGynecologic Oncology, 1997
- Final Results of a Phase II Chemoradiation Protocol for Locally Advanced Cervical Cancer: RTOG 85-15Gynecologic Oncology, 1996
- A possible new trend in the management of the carcinoma of the cervix uteriGynecologic Oncology, 1986
- Radiation and Platinum Drug InteractionInternational Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine, 1985